KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

BusinesswireOct 18 06:30 ET

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Simply Wall StOct 17 10:04 ET

H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsOct 7 06:31 ET · Ratings

KalVista Pharmaceuticals Presents New Data Showing Effectiveness Of Sebetralstat In Reducing Anxiety During Attacks; Supports Need For Oral On-Demand Option To Treat Attacks Earlier And More Often At The 2024 HAEi Global Angioedema Forum

BenzingaOct 4 12:32 ET

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireOct 2 06:30 ET

Express News | Kalvista Pharmaceuticals Inc - Sebetralstat Phase 3 Trial Meets Primary Endpoint

ReutersSep 30 06:30 ET